Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected ...

Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siR…

Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity ...

Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious ...
Open Knowledge Repository - World Bank

Nudging at Scale: Evidence from a Government Text Messaging Campaign during School Shutdowns in Punjab, Pakistan

This brief presents initial findings from an ongoing phone survey of families in Punjab, Pakistan designed to assess what is happening to girls’ elementary school education during COVID-19. The ...